琥珀酸亚铁治疗妊娠合并缺铁性贫血疗效与安全性分析.docVIP

琥珀酸亚铁治疗妊娠合并缺铁性贫血疗效与安全性分析 　　[摘要] 目的 探讨琥珀酸亚铁治疗妊娠合并缺铁性贫血的临床疗效，并分析其安全性。方法 整群选取该院2016年1―12月期间所收治的86例妊娠合并缺铁性贫血妇女作为该次研究对象，对其进行随机分组，研究组和对照组各43例，所有妇女均停用有关补充铁元素的药物，并对红细胞、血红蛋白和血清铁蛋白等血液指标进行检测，对照组妇女应用硫酸亚铁治疗，研究组采取琥珀酸亚铁治疗，对比分析两组患者的临床疗效与治疗前后的血液指标和不良反应发生情况。结果 两组治疗前的血液指标无统计学意义，不良反应发生情况差异无统计学意义（P0.05）。研究组的临床总有效率为95.35%，显著高于对照组74.42%，治疗后，研究组RBC（3.85±0.89）×1012L、Hb（113.72±13.53）g/L、SF（53.68±21.47）μg/L明显优于对照组（3.45±0.65）×1012L、（105.48±10.18）g/L、（40.14±15.40）μg/L，两组差异有统计学意义（P0.05）。结论 琥珀酸亚铁治疗妊娠合并缺铁性贫血的的效果明显，能够有效改善妇女的临床症状，值得推广应用。 　　[关键词] 琥珀酸亚铁；妊娠合并缺铁性贫血；安全性 　　[中图分类号] R4 [文献标识码] A [文章编号] 1674-0742（2017）11（a）-0111-03 　　[Abstract] Objective To study the clinical curative effect and safety of ferrous succinate in treatment of pregnancy and hypoferric anemia and analyze its safety. Methods 86 cases of women with pregnancy and hypoferric anemia admitted and treated in our hospital from January to December 2016 were group selected and randomly divided into two groups with 43 cases in each， all women stopped using the related iron-element tonics， and the red cell， hemoglobin and serum ferroprotein were tested and the control group and the research group were respectively treated with ferrous sulfate and ferrous succinate， and the clinical curative effect and blood indexes and occurrence of adverse reactions before and after treatment were compared between the two groups. Results The differences in the blood indexes between the two groups were not statistically significant， and there was no obvious difference in the occurrence of adverse reactions without statistical significance（P0.05）， and the total clinical effective rate in the research group was obviously higher than that in the control group， （95.35% vs 74.42%）， after treatment， the RBC， Hb and SF in the research group were obviously better than those in the control group， [（3.85±0.89）×1012L， （113.72±13.53）g/L， （53.68±21.47）μg/L vs （3.45±0.65）×1012L， （105.48±10.18）g/L，（40.14±15.40）μg/L]， and the differences were obvious， with statistical s